Research On The Value Evaluation Of Pharmaceutical Enterprise Data Assets

In April 2020,the Opinions of the State Council of the Central Committee of the Communist Party of China on Building a More Perfect Institutional Mechanism for Market-Based Allocation of Factors listed data as one of the five factors of production.Data assetization has become an integral part of the construction of Digital China,and the era of data assets has arrived.As a new type of asset,data will give rise to a new transaction ecology,a new value system and a new commodity form,providing a new impetus for the development of universalization and the digital economy.The pharmaceutical industry is a strategic industry that sustains the livelihood of the nation and is an important foundation for a healthy China.The "14th Five-Year Plan" for the development of the pharmaceutical industry points out that it is necessary to promote the digital transformation of the pharmaceutical industry,and to promote the construction of a digital management system covering disease diagnosis and treatment,drug distribution,medical insurance settlement and other aspects.However,at present,there are few pharmaceutical enterprises that have carried out digital transformation,and the research on the value assessment of data assets of pharmaceutical enterprises is also at a weak stage,so the value assessment of data assets of pharmaceutical enterprises is imminent.In this paper,the connotation,characteristics,classification and status of value evaluation of data assets are reviewed.The concept connotation,extension and value influencing factors of data assets are defined.The evaluation method of pharmaceutical enterprise data assets is analyzed.The initial value of the data asset is calculated by the multi-period excess return method,and the correction coefficient is calculated by the analytic hierarchy process and fuzzy comprehensive evaluation method.Finally,the final value of the data asset is obtained by stripping the value of other assets from the initial value through the correction coefficient.Yunnan Baiyao Co.,LTD.,a benchmark enterprise of digital transformation,is selected as the research object of this paper,and its data asset value is calculated through the model.Finally,some suggestions are put forward for the follow-up valuation of pharmaceutical enterprises.From the evaluation process dimension,develop a better and more rigorous evaluation theoretical framework,build a more scientific and reasonable model;From the evaluation method dimension,researchers focus on the trading market,using fully informed trading information to obtain more scientific and reliable estimates;From the dimension of the evaluation object,using the industrial chain effect,combined with the upstream and downstream data assets of pharmaceutical enterprises in the industrial chain,more fully analyze the influencing factors of pharmaceutical enterprises’ data assets.